StockNews.com downgraded shares of Cellectis (NASDAQ:CLLS - Free Report) from a buy rating to a hold rating in a report published on Thursday morning.
Cellectis Stock Performance
NASDAQ CLLS traded up $0.01 during trading hours on Thursday, hitting $1.39. 6,124 shares of the company's stock traded hands, compared to its average volume of 144,773. Cellectis has a 52 week low of $1.10 and a 52 week high of $3.38. The business's fifty day moving average price is $1.33 and its two-hundred day moving average price is $1.63. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $76.98 million, a P/E ratio of -1.07 and a beta of 3.22.
Cellectis (NASDAQ:CLLS - Get Free Report) last released its earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.22). The firm had revenue of $33.22 million during the quarter, compared to analysts' expectations of $5.90 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. Equities research analysts predict that Cellectis will post -0.46 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 103.4% in the fourth quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 12,500 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Cellectis in the 4th quarter worth $962,000. Finally, B Group Inc. bought a new stake in shares of Cellectis in the 4th quarter worth about $5,547,000. Institutional investors own 63.90% of the company's stock.
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Recommended Stories
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
